Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis

Inclusion Criteria: * Men or women , aged between 18 and 75 years old * Cirrhosis or chronic hepatitis associated with C, B, delta infection or alcool intake or both and confirmed by liver biopsy * One or two HCC nodules treated by surgical or percutaneous ablation (ethanol, acetic acid 50% or radiofrequency). * The efficacy of the initial curative treatment will be assessed by the following criteria: alpha-fetoprotein concentration \< or equal 25ng/ml, no progression in size of the tumour demonstrated by ultrasonography and no arterial hypervascularization on CT scan imaging Exclusion Criteria: * HIV coinfection associated with a CD count\<200/mm3 and a viral charge\>5000 HIV RNA copies/ml * Documented iodine intolerance * Respiratory insufficiency * Decompensated cirrhosis (Child-Pugh score over 8) * Bilirubin concentration over 51 µmol/l * Portal or hepatic vein thrombosis * Extra-hepatic metastasis * Excessive alcohol intake (over 50g per day) * Blood platelet count below 50000/mm3 * Neutrophil count above 1500/mm3 * Creatininemia over 120µmol/l * Myocardial infarction or rhythm disorders * Psychiatric disease with hospitalization * Previous treatment for hepatocellular carcinoma * Pregnant or breastfeeding * Treatment with interferon and/or ribavirin 3 months before inclusion * Treatment with tamoxifen or somatostatin analogs or systemic chemotherapy